نمایش مختصر رکورد

dc.contributor.authorNikkhah, Karimen_US
dc.date.accessioned1399-08-22T00:36:39Zfa_IR
dc.date.accessioned2020-11-12T00:36:39Z
dc.date.available1399-08-22T00:36:39Zfa_IR
dc.date.available2020-11-12T00:36:39Z
dc.date.issued2017-04-01en_US
dc.date.issued1396-01-12fa_IR
dc.identifier.citation(1396). مجله علوم اعصاب شفای خاتم, 5(2), 19-19.fa_IR
dc.identifier.issn2322-1887
dc.identifier.issn2345-4814
dc.identifier.urihttp://shefayekhatam.ir/article-1-1172-en.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/499698
dc.description.abstractAE is a serious medical condition in which the immune system attacks the brain, impairing function. With rapid diagnosis and appropriate treatment, many patients recover most or all functions. However, not all patients experience full recovery; with approximately 6% mortality and other patients who never regain significant brain and/or bodily functions. Autoimmune encephalitis can produce a wide range of neuro-psychiatric symptoms. While the term “autoimmune encephalitis” appears in the medical literature in the 1970’s and 1980’s, the first specific AE antibody was identified in 2005 when Dr. Josep Dalmua described the anti-NMDA-receptor encephalitis type. The disease occurs in men, women and children of all ages. AE is a multi-disciplinary disease. Diagnosis and treatment often requires the combined efforts of multiple specialists including: psychiatrists, neurologists, rheumatologists, and immunologists. As soon as a patient is diagnosed with AE, they should receive one or more of the four (4) first-line treatments. removal of a teratoma (if present) that could be triggering the autoimmune response steroids to reduce immune response and inflammation plasmapheresis to remove harmful antibodies from blood intravenous immunoglobulin (IVIG), which is believed to occupy the binding sites where harmful antibodies attach to brain cells. Second line treatments—immunosuppressant drugs—should be started promptly if first-line treatments fail to improve symptoms. Finally some neurologic article reported that 12% of patients had at least one relapse within two years. en_US
dc.format.extent206
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherتهران مرکز تحقیقات علوم اعصاب شفاءfa_IR
dc.relation.ispartofمجله علوم اعصاب شفای خاتمfa_IR
dc.relation.ispartofThe Neuroscience Journal of Shefaye Khatamen_US
dc.subjectTreatmenten_US
dc.subjectPatienten_US
dc.subjectImmune systemen_US
dc.subjectBasic research in Neuroscienceen_US
dc.titleO 19: Treatment and Porognosis of Autoimmune Encephalitisen_US
dc.typeTexten_US
dc.typeReview --- Open Access, CC-BY-NCen_US
dc.contributor.departmentMashhad University of Medical Sciences, Mashhad, Iranen_US
dc.citation.volume5
dc.citation.issue2
dc.citation.spage19
dc.citation.epage19


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد